Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Gross Margin (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Gross Margin for 6 consecutive years, with 87.24% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 301.0% year-over-year to 87.24%, compared with a TTM value of 85.41% through Dec 2025, up 355.0%, and an annual FY2025 reading of 85.41%, up 355.0% over the prior year.
  • Gross Margin was 87.24% for Q4 2025 at Xeris Biopharma Holdings, up from 85.22% in the prior quarter.
  • Across five years, Gross Margin topped out at 87.24% in Q4 2025 and bottomed at 62.01% in Q2 2021.
  • Average Gross Margin over 5 years is 80.18%, with a median of 82.63% recorded in 2022.
  • The sharpest move saw Gross Margin soared 1898bps in 2022, then crashed -808bps in 2024.
  • Year by year, Gross Margin stood at 77.46% in 2021, then rose by 5bps to 81.02% in 2022, then grew by 2bps to 82.95% in 2023, then rose by 2bps to 84.23% in 2024, then increased by 4bps to 87.24% in 2025.
  • Business Quant data shows Gross Margin for XERS at 87.24% in Q4 2025, 85.22% in Q3 2025, and 83.37% in Q2 2025.